Panion in ITF-meeting at EMA

Development of new and unique medicines for animals (and humans) requires a close cooperation with the authorities that in the end will decide on the approval and allow marketing of the product.

In Europe, genetically based novel medicines are authorised by application to the European Medicines Agency (EMA), currently located in London. To facilitate the understanding of new ideas and approaches to treatment of diseases, the EMA has established an Innovation Task Force (ITF) which consists of experienced scientific reviewers and persons involved in the assessment and processing of new medicinal inventions, who will meet with a small number of selected companies each year.

Panion's epilepsy product, which is based on CombiGene's scientific development over many years, was accepted for an ITF meeting in 2018. A briefing package of background infor- mation and research results was send to EMA before the ITF meeting with the experts in London in June 2018. Associate professor at the University of Copenhagen, David Woldbye, led the scientific questions on the project. Chief Research and Development Officer from CombiGene, Karin Agerman, led the discussion on manufacture and product development.

CEO and veterinarian from Panion, Anja Holm, led the presentation and the clinical discussion on the development of the product for animals.

"The meeting was very successful, and our expectations were fully met. We got some new things to think about and new angles that we can use for the benefit of the product development. It was clear that they understand our approach very well. Importantly, we also got a feeling for where the authorities see potential short-cuts that we will explore, and where we need to investigate and explain more thoroughly", says Anja Holm, CEO of Panion Animal Health AB. 

TUE, JUN 12, 2018

For further information, please contact:

Anja E. H. Holm, CEO | + 45-22 94 66 00 anja.holm@panion-animalhealth.com 

Developing animal health - In Panion, we want to improve the quality of life for animals suffering from chronic diseases. We are convinced that gene therapy has promising prospects. Our aim is to develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, based on CombiGene AB's technology and platform. Panion Animal Health AB is listed at AktieTorget. 

Nerladdningsbara filer



The rights issue in Panion Animal Health AB has been registered by the Swedish Companies Registration Office

The rights issue which was decided by the Board of Panion Animal Health AB, with the authorization of the Annual General Meeting of 29 May 2018, has now been registered by the Swedish Companies Registration Office. Shares and share capital after the registration by the Swedish Companies Registration Office amount to SEK 1,137,110.723254 divided into 24,399,487 shares.







Panion starts clinical study in dogs

Panion Animal Health AB develops a novel gene therapy treatment for dogs with epilepsy. The first clinical trial will be conducted at Long Island Veterinary Specialists, Ophthalmology, Surgery, Internal Medicine, Emergency, PLLC ("LIVS") in New York, USA. It is a pilot study to evaluate the efficacy of the treatment in patient dogs with idiopathic epilepsy. It is the first time that the gene therapy treatment is made available for client-owned family dogs.


Invitation to investor meeting in Stockholm, Friday 14th of December 2018, 12-13

Panion Animal Health AB invites all interested persons to an investor meeting at Mangolds offices, Engelbrektsplan 2, Stockholm on Friday the 14th of December 2018 from 12 - 13.


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Sturegatan 32
114 36 Stockholm

08-692 21 90
Kontaktformulär

Kontakta oss

Vill du veta mer om beQuoted och våra tjänster så fyll i nedanstånde uppgifter och tryck skicka.

En av våra rådgivare kontaktar dig inom kort.

Namn: Telefon: E-postadress: Meddelande: